Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-0646
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report ; day:26 ; month:8 ; year:2021 ; pages:1-4
Investigational new drugs ; (26.8.2021), 1-4

Creator
Gelsomino, Francesco
Di Federico, Alessandro
Tardio, Maria Lucia
Grilli, Giada
D’Errico, Antonietta
Ardizzoni, Andrea
Salvagni, Stefania
Contributor
SpringerLink (Online service)

DOI
10.1007/s10637-021-01166-7
URN
urn:nbn:de:101:1-2021111118442553355763
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Gelsomino, Francesco
  • Di Federico, Alessandro
  • Tardio, Maria Lucia
  • Grilli, Giada
  • D’Errico, Antonietta
  • Ardizzoni, Andrea
  • Salvagni, Stefania
  • SpringerLink (Online service)

Other Objects (12)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells

Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Related objects